European Commission authorises fifth safe and effective vaccine against COVID-19
The European Commission yesterday granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine Nuvaxovid, developed by Novavax, the fifth COVID-19 vaccine authorised in the EU.
This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.
The President of the European Commission, Ursula von der Leyen, yesterday said:
“At a time where the Omicron variant is rapidly spreading, and where we need to step up vaccination and the administration of boosters, I am particularly pleased with today's authorisation of the Novavax vaccine. This is the fifth safe and effective vaccine of our vaccine portfolio, offering welcome additional protection to the European citizen against the pandemic. May this authorisation offer a strong encouragement to everyone who has not yet been vaccinated or boosted, that now is the time to do so.”
Stella Kyriakides, Commissioner for Health and Food Safety, yesterday said:
“Today we add a fifth vaccine to our portfolio of safe and effective vaccines. This is our first protein-based vaccine, which shows promising results against COVID-19. Vaccination and boosting to increase protection against COVID-19 is today more important than ever if we are to stem the wave of infections and counter the emergence and spread of new variants. Today we are offering yet another safe and effective vaccine to our citizens, alongside a renewed call to vaccinate, vaccinate, vaccinate!”
On the basis of EMA's positive opinion, the Commission has verified all elements supporting the marketing authorisation and consulted Member States before granting the conditional marketing authorisation.
The Commission signed the contract with Novavax on 4 August 2021. With the conditional market authorisation, Novavax will be able to deliver up to 100 million of their COVID-19 vaccine to the EU starting in the first quarter of 2022. The contract allows Member States to purchase an additional 100 million doses over the course of 2022 and 2023. The first doses are expected to arrive in the first months of 2022 and for this first quarter, Member States have ordered around 27 million doses. This will add to the total amount of 2.4 billion of the vaccine by BioNTech/Pfizer, 460 million doses of the vaccine by Moderna, 400 million by AstraZeneca as well as 400 million doses by Janssen.
Latest News from
Keynote speech by President von der Leyen at the opening ceremony of the Ukraine Recovery Conference05/07/2022 11:15:00
Keynote speech given yesterday by President von der Leyen at the opening ceremony of the Ukraine Recovery Conference.
European Commission proposes first €1 billion tranche of the new macro-financial assistance for Ukraine05/07/2022 09:25:00
The European Commission recently (01 July 2022) proposed a new €1 billion macro-financial assistance (MFA) operation for Ukraine as the first part of the exceptional MFA package of up to €9 billion announced in the Commission's communication of 18 May 2022 and endorsed by the European Council of 23-24 June 2022.
State aid: Commission approves €5 billion French scheme to support energy intensive companies in context of Russia's invasion of Ukraine04/07/2022 16:33:00
The European Commission has approved a €5 billion French scheme to support energy intensive companies across sectors in the context of Russia's invasion of Ukraine.
Consumer protection: Amazon Prime changes its cancellation practices to comply with EU consumer rules04/07/2022 15:25:00
Following a dialogue with the European Commission and national consumer protection authorities, Amazon has committed to bringing its cancellation practices in line with EU consumer rules.
Statement by President von der Leyen at the joint press conference with Prime Minister Fiala on the occasion of the College visit to the Czech Presidency04/07/2022 14:33:00
Statement given recently (01 July 2022) by President von der Leyen at the joint press conference with Prime Minister Fiala on the occasion of the College visit to the Czech Presidency.
Ukraine: Commission waives customs duties and VAT on the import of life-saving goods for Ukrainians04/07/2022 13:25:00
The European Commission recently (01 July 2022) adopted a Decision enabling Member States to temporarily waive customs duties and VAT on the importation from third countries of food, blankets, tents, electric generators and other life-saving equipment destined for Ukrainians affected by the war.
Digital finance: agreement reached on European crypto-assets regulation (MiCA)04/07/2022 12:38:00
The EU brings crypto-assets, crypto-assets issuers and crypto-asset service providers under a regulatory framework for the first time.
Foreign subsidies distorting the internal market: provisional political agreement between the Council and the European Parliament04/07/2022 11:33:00
The Council and the European Parliament recently (30 June 2022) reached a provisional political agreement on the regulation on foreign subsidies distorting the internal market.
State Aid: Commission opens in-depth investigation into Czech support for new nuclear power plant in Dukovany04/07/2022 10:38:00
The European Commission has opened an in-depth investigation to assess whether public support that Czechia plans to grant for the construction of a new nuclear power plant in Dukovany is in line with EU State aid rules.
Sanctions: Council requests European Parliament consent to add the violation of restrictive measures to the list of EU crimes04/07/2022 09:25:00
The Council recently (30 June 2022) requested the European Parliament’s consent on a decision to add the violation of restrictive measures to the list of ‘EU crimes’ included in the Treaty on the Functioning of the EU.